1Q26: CATT1 Enrollment Momentum Building; Ph3 Data Anticipated 1H27

Research evidence excerpt

1Q26: CATT1 Enrollment Momentum Building; Ph3 Data Anticipated 1H27

■ CATT1's use of CGM represents a meaningful methodological improvement over SimpliciT1 and should enhance data quality

and statistical power. A key differentiator of the CATT1 design relative to the SimpliciT1 Phase 2 program is the universal use

of continuous glucose monitoring (CGM) throughout the entire trial. In SimpliciT1, symptomatic hypoglycemia was collected

as a patient-reported adverse event, a methodology that inherently suffers from recall bias, with asymptomatic events being

particularly likely to go unreported. In CATT1, CGM captures glucose readings in real time, including asymptomatic and

nocturnal Level 2 hypoglycemic events that patients would never self-report. The net effect is that CGM should capture more

events per patient, improve completeness of data, and reduce recall bias. CGM also supports patient retention by eliminating

the need for fingerstick blood measurements required in other trials. As a result, CATT1 should benefit from greater statistical

power and higher data quality relative to its predecessor study. Patients must have used a CGM device for at least threeBIOTECHNOLOGY consecutive months prior to screening and may use continuous subcutaneous insulin infusion (CSII/insulin pump) or multiple

daily injections (MDI) for at least six months prior to treatment, remaining on their method of insulin administration for the

entirety of the study. Insulin pumps are set to manual mode for the duration of the study.

■ vTv continued to advance the broader cadisegliatin development program, including progress on supportive trials expectedEQUITY to initiate in 2026. vTv Therapeutics continued working on the design and execution of supportive trials for cadisegliatin,